(Q35937076)

11 August 2017

1 reference

title

Inhibitors in congenital coagulation disorders (English)

1 reference

11 August 2017

Nigel S Key

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

British Journal of Haematology

11 August 2017

published in

1 reference

11 August 2017

volume

127

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

379-391

1 reference

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Natural versus adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

A two-step, two-signal model for the primary activation of precursor helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Orthopaedic surgery in haemophilic patients with inhibitors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Degradation products of factor VIII which can lead to increased immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Views on methods for monitoring recombinant factor VIIa in inhibitor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Is the incidence and prevalence of inhibitors greater with recombinant products? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Immune tolerance induction in hemophilia A: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Should gene therapy be used for newborns with hemophilia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Factor VII gene intronic mutation in a lethal factor VII deficiency: effects on splice-site selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05168.X

10.1111/J.1365-2141.2004.05168.X

21 January 2018

Identifiers

DOI

1 reference

release_zek7wsb5erfm5p4d4xnqyhbyla

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zek7wsb5erfm5p4d4xnqyhbyla

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference